Logo image of ADAP

ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ADAP - US00653A1079 - ADR

0.0549 USD
-0.01 (-15.15%)
Last: 10/27/2025, 10:02:27 PM
0.0579 USD
+0 (+5.46%)
After Hours: 10/27/2025, 10:02:27 PM
Fundamental Rating

2

ADAP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 528 industry peers in the Biotechnology industry. Both the profitability and financial health of ADAP have multiple concerns. ADAP is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • ADAP had negative earnings in the past year.
  • ADAP had a negative operating cash flow in the past year.
  • ADAP had negative earnings in each of the past 5 years.
  • In the past 5 years ADAP reported 4 times negative operating cash flow.
ADAP Yearly Net Income VS EBIT VS OCF VS FCFADAP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

  • ADAP has a worse Return On Assets (-129.95%) than 82.46% of its industry peers.
Industry RankSector Rank
ROA -129.95%
ROE N/A
ROIC N/A
ROA(3y)-39.8%
ROA(5y)-36.38%
ROE(3y)-362.62%
ROE(5y)-240.54%
ROIC(3y)N/A
ROIC(5y)N/A
ADAP Yearly ROA, ROE, ROICADAP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

  • ADAP's Gross Margin of 273.43% is amongst the best of the industry. ADAP outperforms 99.63% of its industry peers.
  • ADAP does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 273.43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADAP Yearly Profit, Operating, Gross MarginsADAP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

1

2. Health

2.1 Basic Checks

  • ADAP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ADAP has been increased compared to 1 year ago.
  • ADAP has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for ADAP is higher compared to a year ago.
ADAP Yearly Shares OutstandingADAP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
ADAP Yearly Total Debt VS Total AssetsADAP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • ADAP has an Altman-Z score of -15.45. This is a bad value and indicates that ADAP is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -15.45, ADAP is doing worse than 80.41% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -15.45
ROIC/WACCN/A
WACC8.77%
ADAP Yearly LT Debt VS Equity VS FCFADAP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 1.52 indicates that ADAP should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.52, ADAP is doing worse than 81.34% of the companies in the same industry.
  • A Quick Ratio of 1.29 indicates that ADAP should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.29, ADAP is doing worse than 83.21% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.52
Quick Ratio 1.29
ADAP Yearly Current Assets VS Current LiabilitesADAP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

5

3. Growth

3.1 Past

  • The earnings per share for ADAP have decreased strongly by -21.05% in the last year.
  • Looking at the last year, ADAP shows a very negative growth in Revenue. The Revenue has decreased by -53.99% in the last year.
  • Measured over the past years, ADAP shows a very strong growth in Revenue. The Revenue has been growing by 175.59% on average per year.
EPS 1Y (TTM)-21.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-108.33%
Revenue 1Y (TTM)-53.99%
Revenue growth 3Y207.05%
Revenue growth 5Y175.59%
Sales Q2Q%-89.33%

3.2 Future

  • Based on estimates for the next years, ADAP will show a very strong growth in Earnings Per Share. The EPS will grow by 38.30% on average per year.
  • The Revenue is expected to grow by 12.60% on average over the next years. This is quite good.
EPS Next Y-152.32%
EPS Next 2Y-63.84%
EPS Next 3Y-34.18%
EPS Next 5Y38.3%
Revenue Next Year-85.59%
Revenue Next 2Y-52.1%
Revenue Next 3Y-13.59%
Revenue Next 5Y12.6%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ADAP Yearly Revenue VS EstimatesADAP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
ADAP Yearly EPS VS EstimatesADAP Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 0.5 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ADAP. In the last year negative earnings were reported.
  • Also next year ADAP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADAP Price Earnings VS Forward Price EarningsADAP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADAP Per share dataADAP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

  • A cheap valuation may be justified as ADAP's earnings are expected to decrease with -34.18% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-63.84%
EPS Next 3Y-34.18%

More info and screens

0

5. Dividend

5.1 Amount

  • ADAP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADAPTIMMUNE THERAPEUTICS-ADR

NASDAQ:ADAP (10/27/2025, 10:02:27 PM)

After market: 0.0579 +0 (+5.46%)

0.0549

-0.01 (-15.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13
Earnings (Next)11-11
Inst Owners31.35%
Inst Owner Change-0.42%
Ins Owners0.29%
Ins Owner Change-0.26%
Market Cap14.55M
Revenue(TTM)65.08M
Net Income(TTM)-169.76M
Analysts40
Price Target0.28 (410.02%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)27.86%
Min EPS beat(2)-24.87%
Max EPS beat(2)80.59%
EPS beat(4)2
Avg EPS beat(4)18.25%
Min EPS beat(4)-75.07%
Max EPS beat(4)92.37%
EPS beat(8)3
Avg EPS beat(8)30.42%
EPS beat(12)6
Avg EPS beat(12)25.8%
EPS beat(16)6
Avg EPS beat(16)-0.97%
Revenue beat(2)2
Avg Revenue beat(2)24.66%
Min Revenue beat(2)15.67%
Max Revenue beat(2)33.64%
Revenue beat(4)3
Avg Revenue beat(4)66.46%
Min Revenue beat(4)-42.36%
Max Revenue beat(4)258.91%
Revenue beat(8)4
Avg Revenue beat(8)34.35%
Revenue beat(12)7
Avg Revenue beat(12)109.28%
Revenue beat(16)8
Avg Revenue beat(16)74.59%
PT rev (1m)0%
PT rev (3m)-75.81%
EPS NQ rev (1m)-41.18%
EPS NQ rev (3m)-44.58%
EPS NY rev (1m)-11.9%
EPS NY rev (3m)-2.29%
Revenue NQ rev (1m)-52.76%
Revenue NQ rev (3m)-75.83%
Revenue NY rev (1m)-21.69%
Revenue NY rev (3m)-44.6%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.22
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.46
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)-0.73
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS0.25
BVpS-0.27
TBVpS-0.28
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -129.95%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 273.43%
FCFM N/A
ROA(3y)-39.8%
ROA(5y)-36.38%
ROE(3y)-362.62%
ROE(5y)-240.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 27.15%
Cap/Sales 4.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.52
Quick Ratio 1.29
Altman-Z -15.45
F-Score1
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)187.66%
Cap/Depr(5y)146.98%
Cap/Sales(3y)39.72%
Cap/Sales(5y)67.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-108.33%
EPS Next Y-152.32%
EPS Next 2Y-63.84%
EPS Next 3Y-34.18%
EPS Next 5Y38.3%
Revenue 1Y (TTM)-53.99%
Revenue growth 3Y207.05%
Revenue growth 5Y175.59%
Sales Q2Q%-89.33%
Revenue Next Year-85.59%
Revenue Next 2Y-52.1%
Revenue Next 3Y-13.59%
Revenue Next 5Y12.6%
EBIT growth 1Y-99.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-99.04%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-33.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.43%
OCF growth 3YN/A
OCF growth 5YN/A

ADAPTIMMUNE THERAPEUTICS-ADR / ADAP FAQ

What is the fundamental rating for ADAP stock?

ChartMill assigns a fundamental rating of 2 / 10 to ADAP.


What is the valuation status of ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) stock?

ChartMill assigns a valuation rating of 0 / 10 to ADAPTIMMUNE THERAPEUTICS-ADR (ADAP). This can be considered as Overvalued.


How profitable is ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) stock?

ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) has a profitability rating of 1 / 10.